Farid Adrienne
Known title: Chief Operations OfficerCIK: 0001867310
Associated companies
Transaction History
| IPSC | ▼ Sell | Open Market | 552 | $343 | 6/9/2025 | View on chart |
| IPSC | ▼ Sell | Open Market | 1,024 | $563 | 5/5/2025 | View on chart |
| IPSC | ▲ Buy | Grant | 120,000 | $0 | 3/11/2025 | View on chart |
| IPSC | ▼ Sell | Open Market | 2,359 | $1K | 3/10/2025 | View on chart |
| IPSC | ▼ Sell | Open Market | 1,054 | $822 | 2/3/2025 | View on chart |
| IPSC | ▼ Sell | Open Market | 1,033 | $1K | 11/4/2024 | View on chart |
| IPSC | ▼ Sell | Open Market | 1,073 | $2K | 8/5/2024 | View on chart |
| IPSC | ▼ Sell | Open Market | 913 | $3K | 5/3/2024 | View on chart |
| IPSC | ▲ Buy | Option Exercise | 22,831 | $24K | 3/7/2024 | View on chart |
| IPSC | ▼ Sell | Open Market | 22,831 | $117K | 3/7/2024 | View on chart |
| IPSC | ▲ Buy | Grant | 24,000 | $0 | 3/7/2024 | View on chart |
| IPSC | ▲ Buy | Option Exercise | 30,684 | $32K | 3/6/2024 | View on chart |
| IPSC | ▼ Sell | Open Market | 30,684 | $152K | 3/6/2024 | View on chart |
| IPSC | ▲ Buy | Option Exercise | 485 | $500 | 2/16/2024 | View on chart |
| IPSC | ▼ Sell | Open Market | 485 | $2K | 2/16/2024 | View on chart |
| IPSC | ▼ Sell | Open Market | 1,784 | $8K | 2/6/2024 | View on chart |
| IPSC | ▼ Sell | Open Market | 2,035 | $8K | 2/5/2024 | View on chart |
| IPSC | ▲ Buy | Grant | 21,875 | $0 | 2/2/2023 | View on chart |
| IPSC | ▲ Buy | Grant | 21,875 | $0 | 2/2/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Century Therapeutics faces competitive pressure on key strategy
A recent analysis suggests that competitors are taking steps to reduce the risks associated with Century Therapeutics' primary business focus. This development is relevant as it may impact the company's market position and future prospects. The stock is currently trading near its support levels, reflecting ongoing uncertainty in the market.
Century Therapeutics faces competitive pressure on key strategy. A recent analysis suggests that competitors are taking steps to reduce the risks associated with Century Therapeutics' primary business focus. This development is relevant as it may impact the company's market position and future prospects. The stock is currently trading near its support levels, reflecting ongoing uncertainty in the market.